Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aurora Digital Medical Device in Generalized Anxiety Disorder
NCT07477990Phase 3Recruiting
- Sponsor
- Psicofarma
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in generalized anxiety disorder (GAD) (2 arms), sponsored by Psicofarma. Primary endpoint: Generalized Anxiety Disorder 7-item scale at 12 weeks. Started Mar 2026; status: recruiting.
02
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07477990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477990.